文献速递乳腺癌放疗放疗物理与技术

加速部分乳腺照射与标准或大分割全乳照射在早期乳腺癌绝经后女性中的经济学评价与预算影响:法国SHARE随机试验结果

Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial.
PubMed 文献 · Radiother Oncol · 2023-07-20

基于法国SHARE随机试验的490例APBI与488例WBI患者数据,从法国国家医保角度进行三年期成本-效用分析。三年时APBI组人均费用2549欧元(±1954)低于WBI组4468欧元(±1586),P值<0.001,QALYs无显著差异;

要点

  • APBI组三年人均费用2549欧元(±1954),WBI组4468欧元(±1586),P值<0.001。
  • 两组QALYs无显著差异。

核心结论

  • 对于早期乳腺癌绝经后女性,APBI治疗可节省费用,且以QALYs衡量的结局无差异。

研究设计与样本

  • 基于法国SHARE随机试验的经济学评价,比较490例随机分配至APBI组(一周内每日两次共十次照射)与488例WBI组(每周五天每日一次,持续三或六周)的绝经后早期乳腺癌低局部复发风险女性。
  • 采用法国国家医保支付方视角,时间跨度为三年,结局指标为质量调整生命年(QALYs),通过概率自举法探索不确定性。

主要发现

  • 三年时APBI组人均费用2549欧元(±1954),WBI组4468欧元(±1586),P值<0.001,放疗是两组费用差异的主要驱动因素。
  • 两组QALYs无显著差异。
  • 敏感性分析纳入交通与病假成本,并基于法国乳腺癌发病率估计开展全国预算影响分析。

关键数值与推荐

  • APBI方案为每周一周内每日两次共十次照射;WBI方案为每周五天每日一次,持续三或六周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This economic evaluation reports the incremental cost-utility ratio and national budget impact in France of accelerated partial breast irradiation (APBI) vs standard or hypofractionated whole breast irradiation (WBI) in breast cancer patients at low risk of local recurrence. MATERIALS AND METHODS: We compared 490 women randomized to the APBI (ten fractions delivered twice daily over one week) with 488 women in the WBI arm (one fraction per day delivered five days per week over three or six weeks). We took the perspective of the French national health insurance with a three-year time horizon. The outcome was quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio was estimated and uncertainty was explored by probabilistic bootstrapping. Transportation and sick leave costs were added in a sensitivity analysis and a national budget impact analysis based on the incidence of breast cancer estimates in France performed. RESULTS: At three years, the average cost per patient was €2,549 (±1,954) in the APBI arm and €4,468 (±1,586) in the WBI arm (p-value < 0.001), radiotherapy was the main driver of the difference between the two arms. No significant difference was found in QALYs. For an average of 60,000 new cases of breast cancer diagnosed annually in France, 28,000 would be eligible for treatment with APBI. A 100% uptake of APBI would result in a yearly30 million€ cost saving. CONCLUSION: APBI for the treatment of postmenopausal women with early-stage breast cancer is cost saving, with no difference in outcome measured by QALYs.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Le Bras A, Belkacemi Y, Bourgier C, et al. Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. Radiother Oncol. 2023. PMID: 37480995. doi:10.1016/j.radonc.2023.109818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。